GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity.

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Anyone using weight loss injections, either through the NHS or privately, has been issued a major warning when it comes to ...